Literature DB >> 8440923

Risk of melanoma and other cancers in melanoma-prone families.

M A Tucker1, M C Fraser, A M Goldstein, D E Elder, D Guerry, S M Organic.   

Abstract

We evaluated the risk of developing melanoma over time in members of 23 melanoma-prone families. All 23 families had dysplastic nevi as well as melanoma. Forty-seven melanomas occurred prospectively, all in family members with dysplastic nevi. The prospective melanomas were markedly thinner than the melanomas diagnosed prior to or at the time of the subject's entry into the study. The cumulative risk of melanoma by age 50 years among people with dysplastic nevi was 48.9% +/- 4.2%. Overall, the relative risk of a prospective melanoma among family members with previous melanoma was 229 (95% confidence interval 110-422). The risk varied by time interval and was 362 in the first 5 years, decreasing to 120 after 5 years. The risk of developing melanoma was 85 times increased (95% confidence interval 41-156) in family members with dysplastic nevi and also declined over time in this group. There was no significant excess of cancers other than melanoma. Close surveillance of these high-risk families has led to diagnosis of melanoma at an earlier developmental stage, which should result in a decrease in mortality over time.

Entities:  

Mesh:

Year:  1993        PMID: 8440923     DOI: 10.1111/1523-1747.ep12470264

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  16 in total

Review 1.  Strategies for early melanoma detection: Approaches to the patient with nevi.

Authors:  Agnessa Gadeliya Goodson; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2009-05       Impact factor: 11.527

2.  Risks of Melanoma and Other Cancers in Melanoma-Prone Families over 4 Decades.

Authors:  Margaret A Tucker; David E Elder; Michael Curry; Mary C Fraser; Virginia Pichler; Deborah Zametkin; Xiaohong R Yang; Alisa M Goldstein
Journal:  J Invest Dermatol       Date:  2018-02-08       Impact factor: 8.551

3.  The dysplastic nevus: from historical perspective to management in the modern era: part I. Historical, histologic, and clinical aspects.

Authors:  Keith Duffy; Douglas Grossman
Journal:  J Am Acad Dermatol       Date:  2012-07       Impact factor: 11.527

4.  Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts.

Authors: 
Journal:  Int J Pancreatol       Date:  1994 Oct-Dec

5.  Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas.

Authors:  Rajmohan Murali; Chris Goumas; Anne Kricker; Lynn From; Klaus J Busam; Colin B Begg; Terence Dwyer; Stephen B Gruber; Peter A Kanetsky; Irene Orlow; Stefano Rosso; Nancy E Thomas; Marianne Berwick; Richard A Scolyer; Bruce K Armstrong
Journal:  Ann Surg Oncol       Date:  2011-09-13       Impact factor: 5.344

Review 6.  Dysplastic nevi and melanoma.

Authors:  Alisa M Goldstein; Margaret A Tucker
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-04       Impact factor: 4.254

7.  Comparative analysis of total body and dermatoscopic photographic monitoring of nevi in similar patient populations at risk for cutaneous melanoma.

Authors:  Agnessa Gadeliya Goodson; Scott R Florell; Mark Hyde; Glen M Bowen; Douglas Grossman
Journal:  Dermatol Surg       Date:  2010-07       Impact factor: 3.398

8.  Perceived intrafamily melanoma risk communication.

Authors:  Lois J Loescher; Janice D Crist; Leilani A C L Siaki
Journal:  Cancer Nurs       Date:  2009 May-Jun       Impact factor: 2.592

9.  Clinical characteristics of cutaneous melanoma and second primary malignancies in a dutch hospital-based cohort of cutaneous melanoma patients.

Authors:  Haike M J van der Velden; Michelle M van Rossum; Willeke A M Blokx; Jan B M Boezeman; Marie-Jeanne P Gerritsen
Journal:  Dermatol Res Pract       Date:  2009-12-31

10.  Skin cancer screening behaviours among individuals with a strong family history of malignant melanoma.

Authors:  N A Kasparian; J K McLoone; B Meiser; P N Butow; J M Simpson; G J Mann
Journal:  Br J Cancer       Date:  2010-10-26       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.